Yaowu He, Yupeng Li, Jing Geng, Hong Chen, Huaping Dai
{"title":"ILDMDB: a manually curated database of metabolite-disease associations in interstitial lung diseases.","authors":"Yaowu He, Yupeng Li, Jing Geng, Hong Chen, Huaping Dai","doi":"10.1007/s11306-026-02440-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Metabolomics analysis shows great promise in identifying non-invasive biomarkers for interstitial lung diseases (ILDs). However, the relevant data are scattered across numerous disparate publications, hindering their full utilization.</p><p><strong>Objectives: </strong>To comprehensively leverage the metabolomic data disseminated throughout the literature, we manually curated and integrated them into the ILDMDB database ( https://ildmdb.shinyapps.io/ILDMDB/ ). This database will be regularly updated and maintained.</p><p><strong>Methods: </strong>We conducted a systematic literature search and extracted key metabolomics data, including changes in metabolites, relevant clinical parameters, and predictive model performance metrics etc. These data were then manually integrated into the ILDMDB database.</p><p><strong>Results: </strong>The current version of ILDMDB contains 3,969 entries, representing 20 ILD types and over 1,000 metabolites derived from Homo sapiens, animal models, and cell line experiments. Each entry comprises detailed information, including the metabolite name, disease type, and original reference. In addition, we have incorporated model data on metabolites used for ILD diagnosis, disease severity, and prognosis, along with information on metabolites associated with clinical parameters. Users can search for target metabolites freely, view their expression patterns and detailed information, and manage metabolite collections in the database.</p><p><strong>Conclusion: </strong>ILDMDB serves as an exploratory platform designed to assist researchers in swiftly and conveniently accessing the metabolic landscape of ILDs, thereby advancing research into the diagnosis, prognosis, and treatment of ILDs from a metabolic perspective.</p>","PeriodicalId":18506,"journal":{"name":"Metabolomics","volume":"22 3","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13124883/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11306-026-02440-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Metabolomics analysis shows great promise in identifying non-invasive biomarkers for interstitial lung diseases (ILDs). However, the relevant data are scattered across numerous disparate publications, hindering their full utilization.
Objectives: To comprehensively leverage the metabolomic data disseminated throughout the literature, we manually curated and integrated them into the ILDMDB database ( https://ildmdb.shinyapps.io/ILDMDB/ ). This database will be regularly updated and maintained.
Methods: We conducted a systematic literature search and extracted key metabolomics data, including changes in metabolites, relevant clinical parameters, and predictive model performance metrics etc. These data were then manually integrated into the ILDMDB database.
Results: The current version of ILDMDB contains 3,969 entries, representing 20 ILD types and over 1,000 metabolites derived from Homo sapiens, animal models, and cell line experiments. Each entry comprises detailed information, including the metabolite name, disease type, and original reference. In addition, we have incorporated model data on metabolites used for ILD diagnosis, disease severity, and prognosis, along with information on metabolites associated with clinical parameters. Users can search for target metabolites freely, view their expression patterns and detailed information, and manage metabolite collections in the database.
Conclusion: ILDMDB serves as an exploratory platform designed to assist researchers in swiftly and conveniently accessing the metabolic landscape of ILDs, thereby advancing research into the diagnosis, prognosis, and treatment of ILDs from a metabolic perspective.
期刊介绍:
Metabolomics publishes current research regarding the development of technology platforms for metabolomics. This includes, but is not limited to:
metabolomic applications within man, including pre-clinical and clinical
pharmacometabolomics for precision medicine
metabolic profiling and fingerprinting
metabolite target analysis
metabolomic applications within animals, plants and microbes
transcriptomics and proteomics in systems biology
Metabolomics is an indispensable platform for researchers using new post-genomics approaches, to discover networks and interactions between metabolites, pharmaceuticals, SNPs, proteins and more. Its articles go beyond the genome and metabolome, by including original clinical study material together with big data from new emerging technologies.